Contact Us |







dayanews emp nodaya


 21 | September | 2015

Pluristem and NIAID Met with U.S. FDA and Agreed on Development Plan for Initiation of Pivotal Study of PLX-R18 in the Treatment of Acute Radiation Syndrome <

Read more >

 10 | September | 2015

Pluristem provides Corporate and Financial Highlights for Fiscal Year 2015<

Read more >

 9 | September | 2015

Pluristem Completed Successful Meeting with the U.S. FDA in Preparation for Filing an IND for PLX-R18 to Treat Incomplete Hematopoietic Recovery after Bone Marrow Transplantation <

Read more >

 6 | September | 2015

Pluristem President Yaky Yanay Elected as Co-Chairman of Israel Advanced Technology Industries <

Read more >

 17 | August | 2015

Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications <

Read more >

 12 | August | 2015

Japan Grants Safety Clearance to Pluristem’s PLX-PAD Cells for Use in Clinical Trials

Read more >

 10 | August | 2015

Pluristem in Key Discussions with Europe’s Adaptive Pathways Group on Phase II Protocol in Critical Limb Ischemia

Read more >

 27 | July | 2015

New Data Show Pluristem’s PLX Cells Regulate the Immune System

Read more >

About hp


Zami Aberman

Zami Aberman

Chairman and CEO

From the CEO


Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to develop and manufacture safe and effective cell therapy products. We believe our cutting edge technology can produce therapies that will help people affected by inflammation, ischemia, hematological disorders, and acute radiation syndrome, and establish us as a leading company in the cell therapy arena. We also believe that in cell therapy “the process is the product”, and precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vital to the success of a cell therapy. Our fully automated process, proprietary 3D cell expansion technology and increasing knowledge of the placental cell drive us to continue developing additional candidates for our product portfolio.


Recently we have made significant progress in the execution of our strategy to shorten the time to commercialization of our PLX cells.

The PLX cell program in critical limb ischemia has been selected for the European Medicines Agency’s Adaptive Pathways pilot project, which potentially allows for early marketing authorization of a therapy in a restricted patient population, and the possibility of later approval for use in broader patient populations. In Japan, we have applied to the Accelerated Pathway for Regenerative Medicine for  our PLX cells in critical limb ischemia. Japan’s Pharmaceuticals and Medical Devices Agency just validated the proposed quality and  large-scale manufacturing methods for PLX-PAD cells for use in clinical trials there. We are hopeful that these rapid pathways will allow us to shorten the time it will take to bring our advanced cell therapies to patients in need of innovative treatments.


Zami Aberman
Chairman and CEO


Pluristem Corporate Presentation, August 2015

Print PDF > Click Here



Pluristem Video




A2015com 01

 catom 01

catom 03

catom 05

catom 07

catom 09

catom 11

catom 13




catom 02

Share Button

The content, text, graphics, data, and services offered herein (the "Content") are provided solely to educate users of this web site on Pluristem and the goods and/or services it provides.  Nothing in the Content should be considered, or used as a substitute for, medical advice, diagnosis or treatment.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.  Reliance on the Content or any portion thereof, or other visitors to the web site, is solely at your own risk.